Revenue and Growth - First quarter 2025 revenue was $2.25 billion, an increase of 19% compared to $1.89 billion in the first quarter of 2024[5] - Instruments and accessories revenue increased by 18% to $1.37 billion, driven by approximately 17% growth in da Vinci procedure volume and approximately 58% growth in Ion procedure volume[6] - The company expects worldwide da Vinci procedure growth of approximately 15% to 17% in 2025, compared to 17% in 2024[19] - Total revenue for the three months ended March 31, 2025, was $2,253.4 million, a decrease of 6.6% from $2,413.5 million in the previous quarter and an increase of 19.2% from $1,890.6 million in the same quarter last year[28] Surgical Systems and Procedures - The company placed 367 da Vinci surgical systems in Q1 2025, compared to 313 in Q1 2024, including 147 da Vinci 5 systems[7] - The installed base of da Vinci surgical systems grew to 10,189 systems as of March 31, 2025, an increase of 15% compared to 8,887 systems as of March 31, 2024[11] Income and Profitability - GAAP net income attributable to Intuitive Surgical, Inc. was $698 million, or $1.92 per diluted share, compared to $545 million, or $1.51 per diluted share, in Q1 2024[9] - Non-GAAP net income attributable to Intuitive Surgical, Inc. was $662 million, or $1.81 per diluted share, compared to $541 million, or $1.50 per diluted share, in Q1 2024[10] - Net income attributable to Intuitive Surgical, Inc. for Q1 2025 was $698.4 million, compared to $685.7 million in Q4 2024 and $544.9 million in Q1 2024, reflecting a year-over-year increase of 28.2%[28] - Diluted net income per share attributable to Intuitive Surgical, Inc. was $1.92 for Q1 2025, compared to $1.88 in Q4 2024 and $1.51 in Q1 2024, representing a year-over-year increase of 27.1%[31] Cash and Assets - The company ended Q1 2025 with $9.10 billion in cash, cash equivalents, and investments, an increase of $269 million during the quarter[12] - Cash, cash equivalents, and investments increased to $9,101.2 million as of March 31, 2025, up from $8,832.4 million at the end of 2024[30] - Total assets rose to $19,220.4 million as of March 31, 2025, compared to $18,743.2 million at the end of the previous quarter[30] - Total liabilities decreased to $2,012.7 million from $2,213.6 million quarter-over-quarter[30] Expenses - Non-GAAP gross profit margin is expected to be within a range of 65% and 66.5% of revenue in 2025, compared to 69.1% in 2024[19] - Non-GAAP operating expense growth is projected to be 10% to 14% in 2025, compared to 10% in 2024[19] - The company reported a significant increase in research and development expenses, totaling $316.2 million for Q1 2025, compared to $294.7 million in Q4 2024 and $284.5 million in Q1 2024[28] - The company continues to face significant recurring expenses related to share-based compensation, which amounted to $36.2 million in Q1 2025[31]

Group 1 - Intuitive Surgical Inc (ISRG) is set to report its first-quarter earnings, with Wall Street expecting earnings per share of $1.72 and revenue of $2.19 billion [1] - The stock has experienced a 28.54% increase over the past year but has faced recent pressure, down 9.5% year to date and 8.77% over the past month [1] - Current stock price is $476.71, which is significantly below all major simple moving averages (SMA) including the 20-day SMA at $489.41 and the 50-day SMA at $523.70 [2][3] Group 2 - The Moving Average Convergence Divergence (MACD) is at a negative 10.71, and the Relative Strength Index (RSI) is at 44.18, indicating weak momentum and potential for further decline [3] - Analysts maintain a consensus rating of Buy for ISRG, with an average price target of $504.31, suggesting a potential upside of 32.02% based on recent bullish calls [5] - The stock was trading at $475.11 at the time of publication, indicating a need for a significant catalyst to reverse the current downtrend [5]

Core Viewpoint - Intuitive Surgical, Inc. (ISRG) is expected to report first-quarter 2025 earnings on April 22, with sales estimated at $2.18 billion and earnings per share at $1.71, reflecting stable earnings estimates for 2025 and 2026 [1][2] Earnings and Estimates - The company has shown a consistent earnings surprise, with a 24.86% surprise in the last quarter and an average surprise of 14.97% over the past four quarters [2] - Current estimates indicate an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold), suggesting uncertainty regarding an earnings beat this time [3] Segment Performance - The Instruments & Accessories segment is anticipated to report strong results due to robust da Vinci procedure growth, particularly in U.S. general surgery and cancer procedures in international markets [4] - The launch of the da Vinci 5 systems is expected to contribute positively to system placements, with 174 systems placed in the U.S. during the fourth quarter, marking a nearly 60% sequential growth [5][9] - The Services segment is likely to reflect strong adoption of digital products, while margins may improve due to cost reductions and lower freight rates, despite increased depreciation expenses [11] Market Trends - General surgery procedures have driven growth in the U.S., while cancer procedures have benefited international markets, a trend expected to continue [7] - China's recovery post-COVID is likely to boost sales, although tariff-related challenges may impact performance [8] - The Systems segment is expected to show strong adoption of the da Vinci 5, although placements in China may face pressure due to delayed tenders [10] Valuation and Performance - ISRG shares have declined 7.5% year-to-date, outperforming the industry decline of 12.6% and the S&P 500's decline of 10.6% [13] - The company is trading at a forward P/E of 57.48X, significantly higher than the industry average of 26.59X, indicating a premium valuation despite a decrease from a five-year high [16] Investment Outlook - Despite high valuation, ISRG is expected to maintain strong performance driven by growth in da Vinci procedure volume and system placements [19] - The launch of new systems in Europe and the U.S. is likely to support growth, although challenges in bariatric procedures and trade tensions may offset some gains [20][21] - Investors are advised to monitor the stock for potential entry points amid tariff uncertainties and high valuation concerns [24][25]

Core Insights - The studies published by Intuitive demonstrate that robotic-assisted surgery (RAS) enhances access to minimally invasive care, particularly in underserved areas, leading to improved patient outcomes [1][2][3] Group 1: Study Findings - The first study identifies regions lacking access to high-quality minimally invasive surgery (MIS) due to factors like training availability and hospital infrastructure [3][4] - The second study evaluates the impact of RAS on MIS rates across 408 U.S. hospitals from 2016 to 2022, focusing on 153 hospitals that adopted RAS for common surgeries [5][6] - Hospitals that implemented RAS saw an increase in MIS rates from 60.5% to 65.8%, compared to a smaller increase from 56.1% to 57.0% in non-RAS hospitals [7] Group 2: Barriers and Solutions - Surgeon characteristics accounted for nearly two-thirds of the variation in MIS use, while patient sociodemographic factors contributed nearly 30% [6][8] - RAS offers a shorter learning curve for surgeons, potentially improving MIS adoption and access [6][8] - Telementoring and remote surgical support can extend the reach of experienced surgeons into underserved areas [6] Group 3: Broader Impact - The introduction of RAS has contributed to overall growth in MIS, rather than merely shifting procedures from traditional laparoscopy [8][9] - More than 16 million patients have benefited from minimally invasive care using Intuitive technologies, leading to shorter recovery times and reduced postoperative complications [9]

In its upcoming report, Intuitive Surgical, Inc. (ISRG) is predicted by Wall Street analysts to post quarterly earnings of $1.71 per share, reflecting an increase of 14% compared to the same period last year. Revenues are forecasted to be $2.18 billion, representing a year-over-year increase of 15.4%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial project ...

Company Overview - Intuitive Surgical, Inc. (ISRG) shares increased by 14.3% to close at $522.95, following a relief rally in global markets due to a 90-day pause on tariff hikes by the United States [1] - The stock had previously experienced a 7.3% loss over the past four weeks [1] Earnings Expectations - The upcoming quarterly earnings for Intuitive Surgical are expected to be $1.71 per share, reflecting a year-over-year increase of 14% [2] - Revenue projections stand at $2.18 billion, which is a 15.4% increase compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Intuitive Surgical has been revised slightly higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - Monitoring the stock is advised to see if the recent price jump can lead to sustained strength [3] Industry Context - Intuitive Surgical is part of the Zacks Medical - Instruments industry, which includes other companies like Steris (STE) [3] - Steris has a consensus EPS estimate of $2.58 for its upcoming report, unchanged over the past month, representing a 7.1% increase from the previous year [4]

Core Insights - Intuitive has received FDA clearance for its SP SureForm 45 stapler, which is designed for use with the da Vinci SP surgical system in thoracic, colorectal, and urology procedures [1][6] - The SP SureForm 45 stapler features SmartFire technology that optimizes tissue compression in real-time, enhancing staple line integrity and minimizing tissue damage [2] - The use of the SureForm 45 stapler in single-port robotic surgery allows surgeons greater control and can reduce operating time [3] Product Features - The da Vinci SP system enables robotic-assisted surgeries with advanced technology that promotes faster patient recovery and less postoperative pain [4] - Surgeons can control up to three wristed instruments and a high-definition 3D camera through a single access point, reducing the risk of external instrument collisions [5] - The da Vinci SP surgical system is approved for various procedures in multiple countries, including the U.S., where it is cleared for urology, transoral otolaryngology, colorectal, and thoracic procedures [6] Company Overview - Intuitive is a leader in minimally invasive care and robotic surgery, with a portfolio that includes the da Vinci surgical system and the Ion endoluminal system [8] - The da Vinci surgical systems are designed to assist surgeons in performing minimally invasive surgeries with high-definition 3D vision and specialized instrumentation [9]

Core Insights - Intuitive Surgical has been a leader in minimally invasive robotic-assisted surgery, achieving a remarkable stock return of 24,632% since its IPO in 2003 [1][2] - Recent global economic concerns and a mixed outlook have led to an 18% decline in shares from their all-time high in January [2] - The da Vinci system has seen significant growth, with nearly 2.7 million procedures performed in 2024, doubling the volume from five years ago [2] Company Developments - The new da Vinci 5 system, approved by the FDA, features over 150 design advancements and 10,000 times more computing power than the previous model, expected to drive future sales growth [3] - The company anticipates a 13% to 16% increase in da Vinci procedure volume for 2025, a slight slowdown from the previous year's 17% growth [4] - Earnings per share (EPS) is projected to grow by 9.6% in 2025, down from 28.5% last year, but analysts expect a rebound to 17.5% growth in 2026 [5][6] Financial Metrics - Revenue growth estimates are 17.2% for 2024, 14.9% for 2025, and 15.6% for 2026 [7] - EPS is projected at $7.34 for 2024, $8.06 for 2025, and $9.47 for 2026 [7] Competitive Landscape - The competitive environment is evolving, with new entrants like Medtronic's Hugo system and Johnson & Johnson's Ottava robot potentially impacting Intuitive's market share [9][10] - CFO Jamie Samath acknowledged that increased competition could lead to longer selling cycles for Intuitive's products [11] Valuation Concerns - Intuitive Surgical's stock is trading at a forward P/E ratio of 63, slightly above its decade average of 62, raising concerns about potential downside if growth expectations are not met [12] - The company is viewed as a leader in healthcare technology, but current stock valuations may deter aggressive investment [13]

Core Insights - The Motley Fool aims to enhance the financial literacy and well-being of individuals by providing investment solutions and market analysis [1] Company Overview - Founded in 1993, The Motley Fool is a financial services company focused on making the world smarter, happier, and richer [1] - The company reaches millions of people monthly through various platforms, including premium investing solutions, free guidance, and market analysis on Fool.com [1] - The Motley Fool also offers top-rated podcasts and operates a non-profit organization, The Motley Fool Foundation [1]

Core Insights - Intuitive has published two peer-reviewed studies demonstrating the effectiveness of its Force Feedback technology in the da Vinci 5 surgical system, which enhances robotic-assisted surgery by allowing surgeons to feel the forces applied to tissue [1][2][8] Group 1: Study Findings - The first study indicated that Force Feedback technology can reduce the force applied to tissue by up to 43%, regardless of the surgeon's experience level, based on evaluations from 28 surgeons [3][4][5] - The second study highlighted that Force Feedback technology improves novice surgeon performance by reducing tissue trauma and errors during suturing, as well as decreasing the time required to complete suturing tasks, evaluated with 29 novice surgeons [6][7] Group 2: Clinical Implications - The studies suggest that the lack of a way to measure forces during surgery can lead to unintentional tissue damage, which may negatively impact patient outcomes such as pain and recovery time [4][5] - The findings indicate that Force Feedback technology could enable gentler robotic surgery, with potential benefits for surgical performance and patient outcomes, although further research is needed to understand its clinical implications [5][8] Group 3: Future Developments - Intuitive is currently expanding the availability of Force Feedback technology in hospitals across the United States and plans to continue its research and development through 2025 and beyond [8]